
Numares has submitted a 501(k) application to the U.S. Food and Drug Administration (FDA) for its new kidney function test, the Axinon glomerular filtration rate nuclear magnetic resonance platform.
In other news, Numares appointed Dr. Gregory Heath, the former general manager of diagnostics at Illumina, as a new member of its supervisory board. He will assist Numares in commercializing its multimarker-based diagnostic tests, including the kidney function test.